Physician
Krinsky, Robert
Krinsky, Robert was paid $142K by Medicaid between Jan 2018 and Sep 2024, across 22 billing codes. Its largest line is 90961, — 48% of everything it billed.
33Billing provider infoKRINSKY, ROBERT
WOODMERE, NY 11598
WOODMERE, NY 11598
33aNPI1942495460assigned 09/07/2007
33bProvider typeNephrology Physician
28Total paid$142K
24GClaims7,930
24DCodes billed22
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other Nephrology Physician providers in New York
Rank by total paid#84 of 559
Median peer was paid$18K
This provider vs. median8.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,466 | $9K | |
| 2019 | 302 | $10K | |
| 2020 | 359 | $15K | |
| 2021 | 546 | $20K | |
| 2022 | 4,745 | $69K | |
| 2023 | 273 | $11K | |
| 2024incomplete | 239 | $8K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90961 | 48% | 1,721 | 1,720 | $69K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 21% | 319 | 302 | $31K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 17% | 891 | 760 | $24K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | 3.1% | 115 | 115 | $4K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.7% | 145 | 129 | $4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 129 | 90 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.7% | 1,630 | 1,265 | $2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.3% | 1,464 | 1,146 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.1% | 48 | 44 | $2K |
| 1111F | <1% | 310 | 267 | $934.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 110 | 75 | $209.85 |
| 3078F | <1% | 183 | 165 | $141.50 |
10 more codes
| 3074F | <1% | 197 | $117.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $105.00 |
| 86328 | <1% | 125 | $54.23 | |
| 3077F | <1% | 30 | $50.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16 | $17.40 |
| 1159F | <1% | 208 | $1.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 87 | $0.00 |
| 1126F | 0% | 70 | $0.00 | |
| 3079F | 0% | 15 | $0.00 | |
| 0521F | 0% | 105 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.